Norwegian Institute of Public Health

Genetic Technologies Reports Q1 FY22 Results

Retrieved on: 
Monday, October 25, 2021

The Multi-Test is a Predictive Panel Risk Test to cover six common cancers which account for ~70% of annual morbidities.

Key Points: 
  • The Multi-Test is a Predictive Panel Risk Test to cover six common cancers which account for ~70% of annual morbidities.
  • Phase one launch to include Breast Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Coronary Artery Disease and Type-2 Diabetes.
  • Commenting on the quarter, CEO Simon Morriss stated: This past quarter demonstrates the forward trajectory and momentum Genetic Technologies has established.
  • Authorised for release by the Board of Genetic Technologies Limited.

GENE Embarks on Breakthrough African American Collaboration for Breast Cancer as Part of Its Commitment to Ethnic Diversity

Retrieved on: 
Tuesday, September 28, 2021

The purpose of the study is to incorporate further research and data on women of African descent to provide expanded testing capabilities for the GeneType for Breast Cancer product.

Key Points: 
  • The purpose of the study is to incorporate further research and data on women of African descent to provide expanded testing capabilities for the GeneType for Breast Cancer product.
  • There exists a significant unmet need for polygenic risk testing for ethnically diverse populations where risks of mortality from Breast Cancer is estimated to be 40% higher in African American women than Caucasian women1.
  • Professor Colditz is a world-renowned figure in breast cancer epidemiology and risk modelling, with notable genotype datasets on the African American population held by the Institute for Public Health.
  • The lifetime probability of developing non-hereditary breast cancer is 11.5% (1 in 9) for the African American population in the USA1.